AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39603709
Drug: ivarmacitinib 4
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivarmacitinib 4 mg
Trial: 39603709
Drug: ivarmacitinib 8
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivarmacitinib 8 mg
Trial: 39603709
Drug: ivarmacitinib 4
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivarmacitinib 4 mg and 8 mg
Trial: 39603779
Drug: Abbreviated antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated antiplatelet therapy (APT) for 1 month
Trial: 39603779
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet therapy (APT) for ≥3 months
Trial: 39604382
Drug: Motor imagery
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor imagery training along with traditional physical therapy program
Trial: 39604779
Drug: Oral betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral betamethasone (BTM) at 0.3 mg/kg/day for 3 days, 0.15 mg/kg/day for 2 days, and 0.05 mg/kg/day on the last day
Trial: 39604779
Drug: Oral betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral betamethasone (BTM)
Trial: 39604957
Drug: Vinorelbine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine at a dose of 25 mg/m2
Trial: 39605008
Drug: 3.5 g
RxNorm normalized name: Calcium 760 MG/3.5 GM Oral Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g resistant potato starch (RPS)
Trial: 39605008
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g resistant potato starch (RPS)
Trial: 39605014
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (Arm C)
Trial: 39605077
Drug: 800 ml
RxNorm normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 ml total bacterial count fecal microbiota transplantation
Trial: 39605077
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml total bacterial count fecal microbiota transplantation
Trial: 39605293
Drug: Resistance Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance Exercise Combined with Cognitive Intervention Therapy
Trial: 39605874
Drug: Elamipretide 40
RxNorm normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elamipretide 40 mg daily subcutaneous administration for 48 weeks followed by a 4-week follow-up period.
Trial: 39606219
Drug: SOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOX regimen chemotherapy (S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2) combined with tislelizumab and low-dose radiation therapy (LDRT)
Trial: 39606707
Drug: Biopsychosocial rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biopsychosocial rehabilitation therapy (personalized program based on one of three rehabilitation treatment modules: graded activity, exposure)
Trial: 39606837
Drug: Galinpepimut-S (WT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galinpepimut-S (WT1 peptide vaccine)
Trial: 39607652
Drug: Radiation exposure
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation exposure treatment
Trial: 39607729
Drug: Everolimus (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (4.5 mg/m)
Trial: 39608001
Drug: Sleep Treatment
RxNorm normalized name: Sleep
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sleep Treatment Education Program (STEP-1)
Trial: 39608608
Drug: Low-AF maize
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-AF maize and groundnut flours provided monthly to the intervention group.
Trial: 39608608
Drug: Skin lotion
RxNorm normalized name: Silicone Skin Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin lotion distributed monthly to the control group.
Trial: 39608975
Drug: Sintilimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (3 mg/kg for body weight <60 kg; 200 mg for ≥60 kg) every 3 weeks until 24 months or 35 cycles and 3 doses of the HPV quadrivalent vaccine (initial dose prior to sintilimab initiation, with subsequent doses at 2 and 6 months)
Trial: 39608989
Drug: Intralesional rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intralesional rituximab injection
Trial: 39608989
Drug: Involved site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved site radiation therapy (ISRT)
Trial: 39609094
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (125 mg weekly) + standard of care (SOC)
Trial: 39609094
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (125 mg weekly) continued
Trial: 39609094
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (125 mg weekly) in non-dermatomyositis (DM) group
Trial: 39609094
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (125 mg weekly) in DM group
Trial: 39609274
Drug: Low-dose (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (0.05 mCi/kg) group
Trial: 39609274
Drug: High-dose (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (0.1 mCi/kg) group
Trial: 39609822
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg with piperaquine 640 mg
Trial: 39609822
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg with piperaquine 960 mg
Trial: 39609822
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg with piperaquine 1440 mg
Trial: 39610761
Drug: ACQUIRE Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACQUIRE Therapy
Trial: 39610995
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (3 weekly supervised sessions: 35 min moderate-intensity treadmill walking + 25 min strength exercises, starting at gestational weeks 12-18)
Trial: 39611098
Drug: Sequential extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential extracorporeal blood purification (EBP) therapies; specific hemofilter prescription, dose, and anticoagulation strategies not detailed.
Trial: 39611098
Drug: Personalized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized treatment based on clinical and molecular data; details on dosage and duration not specified.
Trial: 39611098
Drug: Dynamic CRRT
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic CRRT prescription; details on dosage and duration not specified.
Trial: 39611771
Drug: secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 300 mg every 2/4 weeks (SECQ2W/SECQ4W)
Trial: 39612802
Drug: Pn-MAPS24v (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pn-MAPS24v (1 μg, 2 μg, or 5 μg per PS)
Trial: 39612919
Drug: Nab-paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (125 mg/m2 weekly) with trastuzumab and pertuzumab
Trial: 39612921
Drug: Low-dose ChAdOx1.tHIVconsv1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose ChAdOx1.tHIVconsv1 (C1)
Trial: 39612921
Drug: Full-dose ChAdOx1.tHIVconsv1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose ChAdOx1.tHIVconsv1 (C1) boosted by MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4)
Trial: 39612921
Drug: Vaccine-elicited T-cell
RxNorm normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-elicited T-cell frequencies
Trial: 39612928
Drug: Control (rifampicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (rifampicin, isoniazid, ethambutol, and pyrazinamide combination therapy)
Trial: 39613097
Drug: Dupilumab (100/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (100/200 mg by body weight) every 2 weeks for 52 weeks
Trial: 39613100
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin therapy in monotherapy
Trial: 39613100
Drug: LLT combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLT combination therapy
Trial: 39613100
Drug: No lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-lowering therapy (LLT)
Trial: 39613120
Drug: Maribavir 400
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir 400 mg twice daily (n=142)
Trial: 39613120
Drug: Investigator-assigned therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator-assigned therapy (IAT) (n=69)
Trial: 39613428
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg verapamil administered orally once daily
Trial: 39613437
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) at 2.0 ATA for 90 minutes
Trial: 39613437
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care for VOCs (including hydration, analgesics, normobaric oxygen therapy, and when medically indicated, antibiotic therapy and/or transfusions)
Trial: 39614356
Drug: Daily average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily average concentrations of PM
Trial: 39614356
Drug: Daily average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily average concentrations of nitrogen dioxide (NO2)
Trial: 39614707
Drug: Sildenafil (phosphodiesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (phosphodiesterase inhibitor)
Trial: 39614857
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Glasses (VR-G) - patients watched a 360-degree video with nature sounds before surgery
Trial: 39614865
Drug: Compression tights
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compression tights ON (AM-ON) during medications
Trial: 39614865
Drug: Compression tights
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compression tights OFF (AM-OFF) during medications
Trial: 39614986
Drug: Biphasic cartilage-repair
RxNorm normalized name: SHARK CARTILAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic cartilage-repair implant (BiCRI)
Trial: 39615342
Drug: COVIVAC 3
RxNorm normalized name: COVID-19 LAV Non-US Vaccine (COVIVAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVIVAC 3 μg
Trial: 39615342
Drug: COVIVAC 6
RxNorm normalized name: COVID-19 LAV Non-US Vaccine (COVIVAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVIVAC 6 μg
Trial: 39615398
Drug: 12-month intervention
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month intervention integrating a Diabetes Prevention Program-based behavioral weight loss treatment with problem-solving therapy for depression
Trial: 39615618
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT; acetyl-salicylic-acid 100mg plus clopidogrel 75mg daily)
Trial: 39615889
Drug: 1 weekly
RxNorm normalized name: granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 weekly IA injection of 5 mL PRP for 3 weeks
Trial: 39616365
Drug: FallFitness exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FallFitness exercise program (multicomponent exercise program delivered weekly for 8 weeks)
Trial: 39617017
Drug: CTX130 (volamcabtagene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX130 (volamcabtagene durzigedleucel) at dose level 3 and higher
Trial: 39617030
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human prourokinase (15 mg bolus followed by 20 mg infusion within 30 min)
Trial: 39617030
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human prourokinase
Trial: 39617030
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase (0.9 mg per kg, maximum dose 90 mg; 10% bolus followed by remainder as infusion over 60 min)
Trial: 39617145
Drug: Mirvetuximab soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirvetuximab soravtansine (MIRV) 6 mg/kg adjusted ideal body weight every 3 weeks until progressive disease, unacceptable toxicity, withdrawal of consent, or death
Trial: 39617530
Drug: BI 905677
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 905677 at 2.8 mg/kg every 3 weeks
Trial: 39617530
Drug: BI 905677
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 905677 at 3.6 mg/kg every 3 weeks
Trial: 39617530
Drug: BI 905677
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 905677 (various doses)
Trial: 39617535
Drug: BI 905681
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 905681 (1.0, 2.5, 5.0, 7.0, and 8.5 mg/kg)
Trial: 39617673
Drug: Oxylanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxylanthanum carbonate 1000 mg three times/day
Trial: 39617673
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (LC) 1000 mg three times/day
Trial: 39617826
Drug: Tinostamustine, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinostamustine, 100 mg/m²
Trial: 39617826
Drug: Tinostamustine, RP2D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinostamustine, RP2D (recommended Phase II dose)
Trial: 39618195
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to subtype (esomeprazole for epigastric pain syndrome; itopride for postprandial distress syndrome; itopride with possible switch to esomeprazole at week 4)
Trial: 39618195
Drug: Empirical proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical proton pump inhibitor (esomeprazole only)
Trial: 39618204
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered before extubation
Trial: 39618256
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks on background intranasal corticosteroids
Trial: 39618477
Drug: Exogenous oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous oral progesterone (200 mg twice daily)
Trial: 39618866
Drug: Low lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lung compliance (≤23.8 mL/cmH2O)
Trial: 39618866
Drug: Higher lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher lung compliance (above 23.8 mL/cmH2O)
Trial: 39619495
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (eTAU) control group
Trial: 39620046
Drug: Bimekizumab (BKZ)
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Bimekizumab (BKZ) 160 mg every 2 weeks (Q2W; Weeks 0-10) then 320 mg Q4W (Weeks 12-44)
Trial: 39620046
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg Q2W (Weeks 0-4), then 200 mg Q2W (Weeks 6-10), 400 mg Q4W (Weeks 12-44)
Trial: 39620153
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with standard pharmacological treatment (EG)
Trial: 39620153
Drug: Standard pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological treatment with placebo acupuncture (CG)
Trial: 39620201
Drug: PNET HR+5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNET HR+5 regimen (intensive pediatric chemotherapy)
Trial: 39621728
Drug: DMC laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMC laser diode (λ = 808 nm), 4J per point, 100mW of power, 1,016W/cm2, 8 sites in the vulvar region, four consecutive applications, weekly.
Trial: 39621979
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (n = 15)
Trial: 39622410
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day) plus Ramucirumab (10 mg/kg every two weeks)
Trial: 39622578
Drug: Optimisation to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan
Trial: 39622823
Drug: Adjunctive rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive rosuvastatin
Trial: 39623365
Drug: Mesoglycan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan (200 mg for the first 5 days, then 100 mg for the subsequent 35 days, twice daily)
Trial: 39623426
Drug: ADSC spray
RxNorm normalized name: Asparagus adscendens root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADSC spray therapy
Trial: 39623502
Drug: Extended-release buprenorphine
RxNorm normalized name: Buprenorphine Extended-Release Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release buprenorphine (XR-BUP) - single injection of a 28-day formulation within 72-hours of anticipated hospital discharge.
Trial: 39623502
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) - may consist of any MOUD other than XR-BUP.
Trial: 39623502
Drug: Extended-release buprenorphine
RxNorm normalized name: Buprenorphine Extended-Release Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release buprenorphine (XR-BUP)
Trial: 39623757
Drug: Advanced systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced systemic therapy (AST) including dupilumab and upadacitinib
Trial: 39623757
Drug: Advanced systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced systemic therapy (AST)
Trial: 39624459
Drug: Apomorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine treatment (30-day subcutaneous administration)
Trial: 39624459
Drug: Apomorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine treatment
Trial: 39624736
Drug: Topical OA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical OA 0.5%
Trial: 39624736
Drug: Topical retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical retinol 0.5%
Trial: 39624747
Drug: Microwave treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microwave treatment (Swift device)
Trial: 39624833
Drug: HAIC sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC sequential TAE combined with tislelizumab and surufatinib
Trial: 39624922
Drug: Higher HBcrAg
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher HBcrAg levels at end of treatment (EOT)
Trial: 39625044
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two consecutive markers
Trial: 39625230
Drug: Lebrikizumab 250
RxNorm normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 250 mg every 4 weeks (Q4W) with topical corticosteroids (TCS)
Trial: 39625230
Drug: Lebrikizumab 250
RxNorm normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 250 mg every 2 weeks (Q2W) with topical corticosteroids (TCS)